Staphylococcus aureus GyrB

AZD5099 is an orally effective pyrrole amide inhibitor and antibacterial agent. AZD5099 shows over 10000-fold higher selectivity for bacterial type II topoisomerases than for human topoisomerase IIα, with a IC₅₀ value of 0.032 μmol/L against Staphylococcus aureus GyrB, a IC₅₀ of 0.760 μmol/L against Escherichia coli GyrB, a IC₅₀ of 73 nM against Escherichia coli ParE, a K_d of 83.8 nmol/L for Staphylococcus aureus GyrB, and a IC₅₀ of >50 μM against human topoisomerase IIα. AZD5099 inhibits rat Mrp2 ATPase activity, competitively binds to the ATP-binding site of bacterial type II topoisomerases, blocks enzyme activity, reduces bacterial DNA and RNA synthesis, disrupts DNA replication and transcription processes, and induces mitochondrial toxicity. AZD5099 exhibits activity against Gram-positive bacteria, fastidious Gram-negative bacteria and drug-resistant strains, reduces bacterial loads in mouse infection models, and has a low spontaneous resistance frequency. AZD5099 can be used in studies related to infections caused by Gram-positive bacteria and fastidious Gram-negative bacteria, methicillin-resistant Staphylococcus aureus infections, Streptococcus pneumoniae pulmonary infections, as well as Staphylococcus aureus and Escherichia coli infections .

Antibacterial agent 169 (Compound 28) is a pyrrolamide-type GyrB/ParE inhibitor with antibacterial activity. Antibacterial agent 169 has an inhibitory effect on Gyrase and Topo IV of Staphylococcus aureus, with IC₅₀ values of 49 nmol/L and 1.513 μmol/L respectively .

Antibacterial agent 365 is a benzothiazole-based antibacterial agent that primarily exerts its effects by disrupting bacterial cell membranes. Antibacterial agent 365 exhibits a MIC of 4 μg/mL against Staphylococcus aureus ATCC 29213, MRSA ATCC BAA41 and MRSA ATCC 43300. Antibacterial agent 365 can be used in studies of MRSA infection, bacterial cell membrane disruption, biofilm formation and antimicrobial resistance .